Literature DB >> 15919951

Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1.

Shixia Wang1, James Arthos, John M Lawrence, Donald Van Ryk, Innocent Mboudjeka, Siyuan Shen, Te-Hui W Chou, David C Montefiori, Shan Lu.   

Abstract

Strategies are needed for human immunodeficiency virus type 1 vaccine development that improves the neutralizing antibody response against primary isolates of the virus. Here we examined recombinant DNA priming followed by subunit protein boosting as a strategy to generate neutralizing antibodies. Both plasmid-based and recombinant protein envelope (Env) glycoprotein immunogens were derived from a primary viral isolate, JR-FL. Serum from rabbits immunized with either gp120 or gp140 DNA vaccines delivered by gene gun inoculation followed by recombinant gp120 protein boosting was capable of neutralizing JR-FL. Neither the DNA vaccines alone nor the gp120 protein alone generated a detectable neutralizing antibody response against this virus. Neutralizing antibody responses using gp120 DNA and gp140 DNA for priming were similar. The results suggest that Env DNA priming followed by gp120 protein boosting provides an advantage over either approach alone for generating a detectable neutralizing antibody response against primary isolates that are not easily neutralized.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15919951      PMCID: PMC1143658          DOI: 10.1128/JVI.79.12.7933-7937.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  22 in total

Review 1.  Human trials of HIV-1 vaccines.

Authors:  M J Mulligan; J Weber
Journal:  AIDS       Date:  1999       Impact factor: 4.177

Review 2.  Vaccines for the prevention of HIV-1 disease.

Authors:  J R Mascola; G J Nabel
Journal:  Curr Opin Immunol       Date:  2001-08       Impact factor: 7.486

Review 3.  HIV vaccines 1983-2003.

Authors:  Andrew J McMichael; Tomas Hanke
Journal:  Nat Med       Date:  2003-07       Impact factor: 53.440

4.  Urgently needed: a filter for the HIV-1 vaccine pipeline.

Authors:  John P Moore; Dennis R Burton
Journal:  Nat Med       Date:  2004-08       Impact factor: 53.440

5.  HIV vaccine design and the neutralizing antibody problem.

Authors:  Dennis R Burton; Ronald C Desrosiers; Robert W Doms; Wayne C Koff; Peter D Kwong; John P Moore; Gary J Nabel; Joseph Sodroski; Ian A Wilson; Richard T Wyatt
Journal:  Nat Immunol       Date:  2004-03       Impact factor: 25.606

Review 6.  Prospects for vaccine protection against HIV-1 infection and AIDS.

Authors:  Norman L Letvin; Dan H Barouch; David C Montefiori
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

7.  Polyvalent DNA prime and envelope protein boost HIV-1 vaccine elicits humoral and cellular responses and controls plasma viremia in rhesus macaques following rectal challenge with an R5 SHIV isolate.

Authors:  Ranajit Pal; Shixia Wang; V S Kalyanaraman; B C Nair; Stephen Whitney; Timothy Keen; Lindsey Hocker; Lauren Hudacik; Nicolas Rose; Anthony Cristillo; Innocent Mboudjeka; Siyuan Shen; Te-Hui Wu-Chou; David Montefiori; John Mascola; Shan Lu; Phillip Markham
Journal:  J Med Primatol       Date:  2005-10       Impact factor: 0.667

8.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

Review 9.  Immunopathogenesis and immunotherapy in AIDS virus infections.

Authors:  Norman L Letvin; Bruce D Walker
Journal:  Nat Med       Date:  2003-07       Impact factor: 53.440

10.  Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen.

Authors:  Louisa Leung; Indresh K Srivastava; Elaine Kan; Harold Legg; Yide Sun; Catherine Greer; David C Montefiori; Jan zur Megede; Susan W Barnett
Journal:  AIDS       Date:  2004-04-30       Impact factor: 4.177

View more
  52 in total

1.  Design of a non-glycosylated outer domain-derived HIV-1 gp120 immunogen that binds to CD4 and induces neutralizing antibodies.

Authors:  Sanchari Bhattacharyya; Roshan Elizabeth Rajan; Yalla Swarupa; Ujjwal Rathore; Anjali Verma; Ranga Udaykumar; Raghavan Varadarajan
Journal:  J Biol Chem       Date:  2010-06-17       Impact factor: 5.157

Review 2.  Effect of vaccine administration modality on immunogenicity and efficacy.

Authors:  Lu Zhang; Wei Wang; Shixia Wang
Journal:  Expert Rev Vaccines       Date:  2015-08-27       Impact factor: 5.217

3.  Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity.

Authors:  Michael Vaine; Shixia Wang; Anthony Hackett; James Arthos; Shan Lu
Journal:  Vaccine       Date:  2010-02-17       Impact factor: 3.641

4.  A versatile vector for the production of pseudotyped viruses expressing gp120 antigens from different clades of primary HIV-1 isolates.

Authors:  Zheng Wang; Mingshun Zhang; Yan Wang; Yanmei Jiao; Lu Zhang; Lin Li; Zuhu Huang; Hao Wu; Jingyun Li; Shan Lu; Shixia Wang
Journal:  J Virol Methods       Date:  2010-10-27       Impact factor: 2.014

Review 5.  Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.

Authors:  Barton F Haynes; David C Montefiori
Journal:  Expert Rev Vaccines       Date:  2006-06       Impact factor: 5.217

Review 6.  Combination DNA plus protein HIV vaccines.

Authors:  Shan Lu
Journal:  Springer Semin Immunopathol       Date:  2006-09-21

7.  Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs.

Authors:  Yuuei Shu; Sarah Winfrey; Zhi-Yong Yang; Ling Xu; Srinivas S Rao; Indresh Srivastava; Susan W Barnett; Gary J Nabel; John R Mascola
Journal:  Vaccine       Date:  2006-11-07       Impact factor: 3.641

8.  A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component.

Authors:  Christine A Bricault; James M Kovacs; Joseph P Nkolola; Karina Yusim; Elena E Giorgi; Jennifer L Shields; James Perry; Christy L Lavine; Ann Cheung; Katharine Ellingson-Strouss; Cecelia Rademeyer; Glenda E Gray; Carolyn Williamson; Leonidas Stamatatos; Michael S Seaman; Bette T Korber; Bing Chen; Dan H Barouch
Journal:  J Virol       Date:  2014-12-24       Impact factor: 5.103

9.  The role of follicular helper T cells and the germinal center in HIV-1 gp120 DNA prime and gp120 protein boost vaccination.

Authors:  Kristin Hollister; Yuxin Chen; Shixia Wang; Hao Wu; Arpita Mondal; Ninah Clegg; Shan Lu; Alexander Dent
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

10.  Improvement of antibody responses by HIV envelope DNA and protein co-immunization.

Authors:  Franco Pissani; Delphine C Malherbe; Jason T Schuman; Harlan Robins; Byung S Park; Shelly J Krebs; Susan W Barnett; Nancy L Haigwood
Journal:  Vaccine       Date:  2013-11-23       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.